logo
Prosperous Health: Revolutionizing Behavioral Healthcare Through Expertise and Innovation

Prosperous Health: Revolutionizing Behavioral Healthcare Through Expertise and Innovation

California, United States, April 23, 2025 -- In an era when mental health and addiction treatment needs are rising nationwide, Prosperous Health is redefining behavioral healthcare with an innovative approach that combines operational excellence and progressive treatment models. Based in Southern California, the organization functions as both a Managed Service Organization (MSO) and a facility owner, and is preparing to open a new facility offering Partial Hospitalization Program (PHP), Intensive Outpatient Program (IOP), and Outpatient (OP) services for mental health and substance use disorders.
Prosperous Health's leadership team brings a unique blend of clinical knowledge and personal recovery experience. CEO JD Meints, who has 13 years of sobriety and over a decade of facility operations experience, says that the company's approach 'allows facilities to focus on their core mission: delivering exceptional care to patients.' Having created multiple nationally recognized programs, including one of the first virtual PHP/IOP offerings in the country, he emphasizes the importance of meeting modern treatment demands.
COO Jerry Shirey, himself with 11 years in recovery, adds that their model 'goes beyond traditional treatment' by integrating technology, evidence-based practices, and compassionate support systems. Shirey's background includes securing more than $25 million in grant funding and leading the introduction of the first ASAM 3.3 Level of Care in the region. His expertise in bridging clinical strategies with innovative solutions has helped shape the way Prosperous Health expands treatment options.
The company's leadership is further strengthened by Chief Medical Officer Dr. Matin Hemmat, a board-certified specialist in both Addiction Medicine and Internal Medicine and a recipient of multiple 'Physician of the Year' awards. His focus ensures that Prosperous Health maintains cutting-edge medical practices centered on patient welfare and measurable outcomes.
As an MSO, Prosperous Health provides comprehensive administrative and operational support, relieving facilities of regulatory and compliance burdens and enabling them to dedicate more resources to direct patient care. This specialization in behind-the-scenes logistics helps align clinical excellence with efficient and sustainable operations, addressing pressing industry challenges.
One of the company's most notable innovations is its Recovery Campus Concept, which reimagines the physical design of treatment settings. Rather than adhering to institutional layouts, these campuses bring together various levels of care—PHP, IOP, and OP—into an integrated environment specifically designed to foster healing and recovery. This thoughtful approach offers continuity for patients, ensuring they receive a seamless experience from intake to continuing care.
Prosperous Health also recognizes that many individuals lack access to in-person treatment. To tackle this challenge, it has embraced technology-based solutions, developing HIPAA-secure digital platforms that enable facilities to reach underserved communities or those who simply cannot attend treatment on-site. By integrating telehealth services, Prosperous Health meets modern healthcare realities and ensures more people can find the specialized support they need.
In addition to offering comprehensive administrative services and forward-thinking treatment models, Prosperous Health sets higher standards for the industry at large. Through new facility designs and pioneering programs, it aims to establish benchmarks that can be adapted by other providers. The introduction of the first ASAM 3.3 Level of Care in the region exemplifies this leadership, as it provides a template for broader implementation of advanced treatment modalities.
'Together, we are not just managing facilities—we are redefining how care is delivered and transforming the lives of thousands,' Shirey observes, reflecting the collective vision that drives Prosperous Health forward. As the organization prepares to open its newest facility, it stands at the intersection of operational innovation, clinical expertise, and a profound commitment to making treatment both accessible and effective.
With behavioral health challenges expanding, Prosperous Health's blueprint demonstrates how evolving beyond conventional frameworks can offer life-changing support to those who need it most. By blending operational efficiency, evidence-based practices, and cutting-edge technology, the company shows what is possible for the future of mental health and substance use disorder treatment.
Release ID: 89157174
If you encounter any issues, discrepancies, or concerns regarding the content provided in this press release that require attention or if there is a need for a press release takedown, we kindly request that you notify us without delay at error@releasecontact.com (it is important to note that this email is the authorized channel for such matters, sending multiple emails to multiple addresses does not necessarily help expedite your request). Our responsive team will be available round-the-clock to address your concerns within 8 hours and take necessary actions to rectify any identified issues or guide you through the removal process. Ensuring accurate and reliable information is fundamental to our mission.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Parkston's Wickersham appointed to Rural Medicine dean role at Sanford School of Medicine
Parkston's Wickersham appointed to Rural Medicine dean role at Sanford School of Medicine

Yahoo

time23-05-2025

  • Yahoo

Parkston's Wickersham appointed to Rural Medicine dean role at Sanford School of Medicine

May 22—PARKSTON, S.D. — Dr. Jason Wickersham has been named Associate Dean of Rural Medicine at the Sanford School of Medicine (SSOM), a position he has held on an interim basis since April 2024. In addition to this role, he will continue practicing family medicine at Avera St. Benedict Health Center in Parkston. In the position of associate dean of rural medicine, Wickersham will help advance the school's mission to provide a workforce pipeline for rural South Dakota. He will collaborate with rural physicians, ensuring that medical students have meaningful experiences in rural areas, and design and support pathway programs that introduce the youth of rural South Dakota to medical careers. Wickersham will also provide leadership and oversight of all academic, research and public service programs for rural medicine sites, while fostering student professionalism and ethical behavior, and mentoring academic and clinical faculty. A 2001 graduate of the Sanford School of Medicine, Wickersham completed his residency at the Nebraska Medical Center's Clarkson Family Practice Residency Program in Omaha, Neb. He was named the 2025 Physician of the Year by the South Dakota Academy of Family Physicians, and in 2023 he was given the Edward J. Batt, M.D., Memorial Teaching Award from the SSOM. Wickersham is a member of Alpha Omega Alpha Honor Society, the American Medical Association and the American Academy of Family Physicians, at both the state and national levels. He also serves on the Avera Health Board of Directors and the SDSMA PAC Board of Directors.

Dr. Kate Viola, MD, MHS, FAAD
Dr. Kate Viola, MD, MHS, FAAD

Business Journals

time13-05-2025

  • Business Journals

Dr. Kate Viola, MD, MHS, FAAD

Health Care | Professional Recognition Dr. Kate Viola, MD, MHS, FAAD, Recognized at Dermatology Partners Dr. Kate Viola, a board-certified dermatologist at Dermatology Partners, has been named a Health Care Hero in the Physician of the Year category by The Daily Record for her volunteer work with veterans and school children. The award honors those who advance health care in Maryland, a national leader in medical research and innovation. Dermatology Partners is the Mid-Atlantic's premier, privately owned and physician-led dermatology practice, with offices in Westminster, Owings Mills, and Sparks.

Hype Or Hope? Latest Research On GLP-1 Receptor Agonists And Addiction
Hype Or Hope? Latest Research On GLP-1 Receptor Agonists And Addiction

Forbes

time06-05-2025

  • Forbes

Hype Or Hope? Latest Research On GLP-1 Receptor Agonists And Addiction

getty The talk of the town at this year's American Society of Addiction Medicine (ASAM) Annual Conference was GLP-1 receptor agonists (GLP-1 RAs), generally known as medications to treat obesity. Mainstream media appears to mirror this trend as nearly every other radio and television ad seemingly involves a weight loss medication. In addition to treating obesity and type 2 diabetes, GLP-1s have also shown promise with substance use disorders (SUD). Because so many questions exist about safety, efficacy, long-term effects and more, ASAM appropriately invited several scientists and clinicians to present the latest data on the role of GLP-1 RAs in addiction. As a physician, even I'm having trouble keeping track of the assembly-line of anti-obesity medicines. The common ones include semaglutide (Ozempic, Wegovy), liraglutide (Victoza), tirzepatide (Mounjaro, Zepbound), dulaglutide (Trulicity) and exenatide (Byetta). They vary in their duration, formulation and other features. What they share, however, is a common lizard origin—the Gila monster. Origin Story Starts With A Venomous Lizard Copyright 2019 The Associated Press. All rights reserved. Exendin-4, a peptide hormone discovered in 1991 in the venom of the Gila Monster, was structurally similar to the human hormone, glucagon-like peptide-1 (GLP-1), explained Joji Suzuki, MD, FACLP, director of the Division of Addiction Psychiatry at Brigham and Women's Hospital. GLP-1s increased the release of insulin but had an extremely short half-life (1-2 minutes), making them highly unfavorable as a treatment for diabetes. The lizard hormone half-life was nearly 100 times longer (~2.5 hours) which led to more research focusing on increasing half-life, resisting degradation and enhancing binding to the GLP-1 receptor. Since that initial discovery nearly four decades ago, the pace of research and publications on GLP-1 RAs has been nothing short of rapid and robust, according to data shown by Dr. Suzuki. Liraglutide began clinical trial in 2000. Exenatide became the first FDA-approved GLP-1 analog in 2005. Semaglutide was approved by the FDA in 2017 as an injectable treatment for type 2 diabetes under the brand name, Ozempic. Tirzepatide was approved in 2022. That same year, GLP-1 drug sales reached $22 billion. Role In Addiction getty GLP-1 receptors are widely located in the brain, notably in the reward centers. Addictive substances such as nicotine, alcohol and opioids hijack the brain's reward pathway to trigger excess release of dopamine, the 'feel-good' neurotransmitter. Studies show that activation of the GLP-1 receptor in the brain reduces dopamine release from addictive substances such as nicotine and alcohol, leading to less cravings and reinforcement. Researchers who are studying the impact of GLP-1 agonists in addiction are hopeful. 'For the first time in a long time, we actually have the possibility for a whole new class of medications our patients [with addiction] might benefit from,' shared Dr. Suzuki. He continued: 'The exciting part is that GLP-1 RAs might benefit a broad range of addictive behaviors including disordered eating or behavioral addictions.' Nicotine Addiction While randomized control trials (RCT) are few, we do have promising preclinical data showing reduced nicotine withdrawal-induced hyperphagia (excessive hunger) and weight gain with liraglutide. In addition, epidemiological studies have demonstrated that patients with type 2 diabetes (T2D) who used GLP-1 RAs were less likely to be diagnosed with nicotine misuse compared to those who used other medicines for T2D. Less healthcare utilization for tobacco use disorder was also associated with this patient group. Like all medicines, GLP-1 RAs are not benign. Luba Yammine, PhD, associate professor of psychiatry at UTHealth Houston, reminded the packed ballroom that common side effects include gastrointestinal symptoms like nausea, vomiting and diarrhea, as well as acute kidney injury. There's also a higher risk of pancreatitis and medullary thyroid cancer. But Dr. Yammine is optimistic, particularly for people who are addicted to several substances: 'A substantial proportion of people with SUD uses multiple substances. Pending positive outcomes from ongoing and forthcoming RCTs, GLP-1 RA medications may become a pharmacotherapeutic approach for treating polysubstance use.' getty Alcohol Addiction Among all substances, alcohol is by far the most investigated when it comes to GLP-1 RAs. Michael Weaver, MD, professor of psychiatry at UTHealth Houston, highlighted research showing that GLP-1 RAs reduced alcohol consumption in vervet monkeys which are alcohol-preferring primates. Stephanie Weiss, MD, PhD, Assistant Director for Clinical Research, Medication Development Program at NIDA, shared data from the first published clinical trial of GLP-1 RAs in alcohol use disorder: in patients with obesity with a BMI over 30, exenatide reduced heavy drinking days by 23.6% and lowered total alcohol intake. She also shared multiple, ongoing NIDA-funded clinical trials including Semaglutide Therapy for Alcohol Reduction or STAR which is currently recruiting patients. What About Other Drug Addictions? We have limited research on cocaine, according to Dr. Weaver. So far, an experimental (not FDA-approved) GLP-1 agonist compound has been shown to lower cocaine self-administration in rats. We don't have much data for opioids, either. One study revealed that repeated doses of liraglutide ('Victoza') decreased heroin self-administration in rats. Experts are cautious but optimistic. 'Clinical research is necessary. Watch this space,' Dr. Weaver advised the captive audience. getty Ethical Issues Regarding GLP-1 Medications The eruption of GLP-1 RAs has several societal implications including equitable access. Nancy Shenoi, MD, assistant professor of psychiatry at Baylor College of Medicine, pointed out gaps in obesity treatment in low- and middle-income countries and rural areas. She also shared that only four countries offer insurance coverage for obesity treatment: Brazil, Canada, Chile and the U.S. Canada's universal healthcare system and lower prices for diabetes medications enhance accessibility. In addition, the Inflation Reduction Act of 2022 allowed Medicare to negotiate the price of 10 costly medications without a generic; no GLP-1 RA is on this list. Mental health must also be a consideration, stated Dr. Shenois, as some studies suggest that liraglutide and semaglutide may trigger suicidal thoughts, self-injury and depression. Bottom Line Current data on GLP-1 receptor agonists and addiction is certainly promising. Decreased mortality, anti-inflammatory properties and neuroprotective effects can be beneficial in chronic substance use which is associated with neuroinflammation and oxidative stress. But there was a clear consensus among experts at the ASAM conference: more research is needed. 'What we urgently need now are rigorous studies to establish both safety and efficacy of GLP-1 agonists,' reminded Dr. Suzuki. We also need patience. 'Let's not all just jump on the band wagon. Results from clinical trials are years away,' emphasized Dr. Weaver. Lipi Roy, MD, MPH Every presenter also agreed that while we're waiting for the science, let's not forget that we already have anti-addiction medications that work but they're grossly underutilized. Only 1 in 5 people with opioid use disorder and less than 8% of those with alcohol use disorder receive treatment. As an addiction medicine doctor, I cannot underscore this point enough: methadone, buprenorphine, naltrexone and nicotine replacement therapy are safe and effective but unacceptably under-prescribed. Let's maximize existing, lifesaving and transformative medicines for people with addiction while also exploring innovative therapeutic options like GLP-1 receptor agonists.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store